Chemioterapia ad alte dosi del carcinoma metastatico della mammella

Translated title of the contribution: High-dose chemotherapy in metastatic breast cancer

A. Tartarone, M. Aieta, M. G. Morritti, G. Palomba, M. P. Romano, G. Lelli

Research output: Contribution to journalArticlepeer-review


Purpose: To evaluate efficacy and toxicity of high-dose chemotherapy (HDCT) in metastatic breast cancer (MBC). Materials and Methods: A literature search from January 1988 until July 1998 about the treatment of metastatic breast cancer with high dose chemotherapy was conducted. Results: After HDCT the overall response rate was about 80%, with 50% of complete remissions. The median survival was > 18 months. Approximately 20% of the patients experienced long-term progression-free survival. Conclusions: Although current results appear promising, randomised trials are required to determine the role of HDCT in the treatment of patients with MBC.

Translated title of the contributionHigh-dose chemotherapy in metastatic breast cancer
Original languageItalian
Pages (from-to)227-230
Number of pages4
JournalClinica Terapeutica
Issue number3
Publication statusPublished - 1998

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'High-dose chemotherapy in metastatic breast cancer'. Together they form a unique fingerprint.

Cite this